64Zn-Enriched Zinc Complexes Modulating Phagocytic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders, particularly Parkinson's disease, are inadequate in effectively addressing the inflammatory processes underlying these conditions, leading to significant challenges in managing the disease progression and symptoms.
Innovation Solution
The use of compositions comprising 64Zn-enriched zinc complexes and 85Rb-enriched rubidium compounds, either alone or in combination, which are administered therapeutically to modulate the inflammatory response and oxidative metabolism in phagocytes, thereby reducing neuronal damage and disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurodegenerative disorders, then disease management is maintained at current levels, but the treatments are inadequate in effectively addressing the inflammatory processes underlying these conditions
Solution Approach 1:
The patent applies parameter changes by using isotopically enriched zinc (64Zn) and rubidium (85Rb) compounds with specific biochemical properties to modify the inflammatory response parameters in neurodegenerative diseases, transforming the treatment approach from conventional to isotopically enhanced therapy
Solution Approach 2:
The patent employs composite materials by combining 64Zn-enriched zinc compounds with 85Rb-enriched rubidium compounds in specific formulations, creating a synergistic therapeutic composition that addresses multiple aspects of neurodegenerative pathology simultaneously
2Reliability
If 64Zn-enriched zinc complexes and 85Rb-enriched rubidium compounds are administered, then phagocytic activity is enhanced and inflammatory shifts are reduced, but the treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic agents (64Zn-enriched zinc complexes and 85Rb-enriched rubidium compounds) into a single combined composition, simplifying administration while maintaining the synergistic therapeutic effects of both isotopically enriched compounds
3Object-affected harmful factors
If isotopically enriched compounds are used to treat neurodegenerative disorders, then neuronal destruction is reduced, but the manufacturing and availability become more challenging
Solution Approach 1:
The patent applies parameter changes by specifying precise isotopic enrichment levels (64Zn and 85Rb) to optimize therapeutic efficacy while reducing neuronal destruction, balancing the manufacturing challenge with clinical benefit through controlled isotopic parameters
Data Source
AI summary
Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.